Get more Mail & Guardian
Subscribe or Login

Single-dose J&J/Janssen Covid-19 vaccine hopes to speed up SA’s vaccination programme

The J&J/Janssen Covid-19 vaccine — manufactured by Janssen Pharmaceuticals Companies of Johnson & Johnson — shows an efficacy rate of 85% against the emerging global Covid-19 variants. 

In South Africa, the Janssen Covid-19 vaccine shows an 82% efficacy rate against severe Covid-19 infections, where the majority of trials (95%) were conducted on the 501Y.V2 (or B.1.351) Covid-19 variant. 

Dr Glenda Gray, president and chief executive of the South African Medical Research Council (SAMRC), presented key findings to parliament on the Johnson & Johnson vaccine product called Ad26.COV2-S, after starting trial proceedings in September 2020. 

Key findings during the third phase of the single-dose trial of Ad26.COV2-S include:

  • 85% vaccine efficacy after 28 days against severe Covid-19 globally, including the United States (US);
  • Consistent vaccine efficacy against severe Covid-19 cases across all regions;
  • The single-dose vaccine offers complete protection against Covid-19 related hospitalisations as of day 28;
  • A 66% vaccine efficacy against moderate to severe/critical Covid-19 across all countries;
  • A single-dose offers protection two weeks after being vaccinated.

With a consistent high efficacy rate, the J&J/Janssen Covid-19 vaccine’s single-dose offers the opportunity to vaccinate the population faster. Gray told parliament that manufacturers are prepared for mass manufacturing of 20-million doses by the end of March, and 100-million doses for the US within the first half of 2021. 

South Africa is in Phase 1 of its nationwide vaccination rollout programme, in which the main focus is to vaccinate healthcare workers. With a target population of over 1.2-million healthcare workers, the latest data reports that 194 257 vaccines had been administered up until 23 March. 

This number concerns Professor Burtram Fielding, a virologist at the University of the Western Cape, who argues the vaccine roll-out plan “is progressing too slow“ while “a third wave is inevitable”.

Current Covid-19 status in South Africa

South Africa saw a drop in Covid-19 cases in the last week, with 1 289 cases recorded on 17 March, before dipping to as low as 210 as of 22 March 2021. 

The National Institute for communicable diseases (NICD) latest weekly report (week 10 of 2021) reported the lowest percentage of testing positive cases since May 2020. In week 10, based on data collected up to mid-March 2021, the percentage testing positive was 4.5% — a significant decrease from 34.7% during the peak of South Africa’s second Covid-19 wave. 

In week 10 the Free State recorded an increase in the percentage of positive cases, while the Western Cape, Eastern Cape, KwaZulu-Natal and Gauteng showed a decrease. 

The third wave

A third Covid-19 wave is expected during the winter while concerns of a possible increase after the Easter weekend cannot be dismissed. 

“If the history of pandemics holds true, the third wave should be smaller than the second, with a lower death rate. This should be a result of the immunity developed due to vaccines and natural infections,” asserts Fielding.

He says he would “not be surprised to see the start of the third wave one to two weeks after Easter,” adding “remember, waves can be halted — by lowering infection numbers per day — simply by changing public behaviours for the positive, even in the midst of a [new] wave”.

How long will you wait?

Vaccine Queue Calculator for South Africa

Subscribe for R500/year

Thanks for enjoying the Mail & Guardian, we’re proud of our 36 year history, throughout which we have delivered to readers the most important, unbiased stories in South Africa. Good journalism costs, though, and right from our very first edition we’ve relied on reader subscriptions to protect our independence.

Digital subscribers get access to all of our award-winning journalism, including premium features, as well as exclusive events, newsletters, webinars and the cryptic crossword. Click here to find out how to join them and get a 57% discount in your first year.

Eunice Stoltz
Eunice Stoltz is a junior daily news reporter at the Mail & Guardian. She was previously a freelance journalist and a broadcaster at Maroela Media and Smile90.4FM.

Related stories

WELCOME TO YOUR M&G

If you’re reading this, you clearly have great taste

If you haven’t already, you can subscribe to the Mail & Guardian for less than the cost of a cup of coffee a week, and get more great reads.

Already a subscriber? Sign in here

Advertising

Subscribers only

Fears of violence persist a year after the murder of...

The court battle to stop coal mining in rural KwaZulu-Natal has heightened the sense of danger among environmental activists

Data shows EFF has lower negative sentiment online among voters...

The EFF has a stronger online presence than the ANC and Democratic Alliance

More top stories

Kenya’s beach boys fall into sex tourism, trafficking

In the face of their families’ poverty, young men, persuaded by the prospect of wealth or education, travel to Europe with their older female sponsors only to be trafficked for sex

High court reinstates Umgeni Water board

The high court has ruled that the dissolution of the water entity’s board by Minister Lindiwe Sisulu was unfair and unprocedural

Mkhize throws the book at the Special Investigating Unit

It’s a long shot at political redemption for the former health minister and, more pressingly, a bid to avert criminal charges
Advertising

press releases

Loading latest Press Releases…
×